As one of the largest pharmaceutical and vaccine companies, GSK has used its vast resources to create the next generation of healthcare treatments. The company's innovative new product lineup and expansive list of patent-protected drugs create a wide economic moat, in our opinion.
GSK's next-generation respiratory drugs and HIV drugs look poised for strong growth over the next three years.
HIV patent pressure to GSK's key drugs will likely begin in 2027, setting up a major hurdle for growth later in the decade.
|
Metric
|
GSK
|
PFE
|
MRK
|
|---|---|---|---|
Price/Earnings (Normalized) | 9.45 | 20.99 | 17.22 |
Price/Book Value | 4.43 | 1.85 | 6.52 |
Price/Sales | 1.80 | 2.91 | 4.57 |
Price/Cash Flow | 10.72 | 21.20 | 15.23 |
|
Metric
|
GSK
|
PFE
|
MRK
|
|---|---|---|---|
Quick Ratio | 0.53 | 0.51 | 0.88 |
Current Ratio | 0.82 | 0.86 | 1.47 |
Interest Coverage | 8.35 | −0.88 | 13.07 |
|
Metric
|
GSK
|
PFE
|
MRK
|
|---|---|---|---|
Return on Assets (Normalized) | 11.39% | 3.50% | 15.46% |
Return on Equity (Normalized) | 49.79% | 8.28% | 41.15% |
Return on Invested Capital (Normalized) | 22.82% | 5.39% | 22.92% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| Lgyqhxrwws | Xsg | $802.3 Bil | |||
| Johnson & Johnson
JNJ
| Gtncjbh | Vgjw | $388.0 Bil | |||
| AbbVie Inc
ABBV
| Bmnqxvgj | Hxs | $347.7 Bil | |||
| Merck & Co Inc
MRK
| Wgjggcrn | Wkbml | $284.1 Bil | |||
| Roche Holding AG ADR
RHHBY
| Nrvpxwrpw | Htgrb | $252.2 Bil | |||
| AstraZeneca PLC ADR
AZN
| Bftqdztvm | Chcp | $245.8 Bil | |||
| Novartis AG ADR
NVS
| Ddhwhtzv | Lry | $232.6 Bil | |||
| Amgen Inc
AMGN
| Kvhktbwfsk | Wtvn | $171.8 Bil | |||
| Pfizer Inc
PFE
| Ntvnzggt | Xkjjb | $162.1 Bil | |||
| Sanofi SA ADR
SNY
| Nghwzwrdr | Ynl | $141.7 Bil |
:quality(80)/author-service-images-prod-us-east-1.publishing.aws.arc.pub/morningstar/a90c659a-a3c5-4ebe-9278-1eabaddc376f.jpg)
United States